ExodusPoint Capital Management LP Sells 27,199 Shares of Pulmonx Co. (NASDAQ:LUNG)

ExodusPoint Capital Management LP lowered its stake in Pulmonx Co. (NASDAQ:LUNG) by 36.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,047 shares of the company’s stock after selling 27,199 shares during the period. ExodusPoint Capital Management LP owned 0.12% of Pulmonx worth $326,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in LUNG. Trexquant Investment LP boosted its position in Pulmonx by 510.1% during the 4th quarter. Trexquant Investment LP now owns 93,700 shares of the company’s stock valued at $636,000 after acquiring an additional 78,343 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Pulmonx by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 902,240 shares of the company’s stock worth $6,128,000 after acquiring an additional 9,454 shares in the last quarter. Norges Bank purchased a new position in Pulmonx during the 4th quarter valued at about $1,027,000. American Century Companies Inc. boosted its position in shares of Pulmonx by 8.8% in the 4th quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock worth $236,000 after purchasing an additional 2,810 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Pulmonx by 44.8% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,941 shares of the company’s stock worth $570,000 after acquiring an additional 25,988 shares in the last quarter. Institutional investors own 91.04% of the company’s stock.

Pulmonx Trading Up 0.8 %

Shares of Pulmonx stock opened at $5.25 on Monday. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The stock has a market capitalization of $208.93 million, a PE ratio of -3.65 and a beta of 0.61. Pulmonx Co. has a 1-year low of $4.89 and a 1-year high of $10.01. The company’s fifty day simple moving average is $7.20 and its 200-day simple moving average is $6.77.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The business had revenue of $23.77 million during the quarter, compared to analyst estimates of $22.29 million. As a group, equities analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $7.85, for a total transaction of $157,000.00. Following the sale, the director now directly owns 991,974 shares in the company, valued at $7,786,995.90. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel David Aaron Lehman sold 22,355 shares of Pulmonx stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.65, for a total transaction of $171,015.75. Following the transaction, the general counsel now owns 175,496 shares in the company, valued at approximately $1,342,544.40. This trade represents a 11.30 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 147,986 shares of company stock worth $1,143,673. Company insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on LUNG shares. Jefferies Financial Group initiated coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating on the stock. Morgan Stanley assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They set an “equal weight” rating for the company. D. Boral Capital started coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Citigroup assumed coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.